Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
02:26pm, Tuesday, 30'th Dec 2025
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026?
10:45am, Tuesday, 30'th Dec 2025
Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs.
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever
09:15am, Tuesday, 30'th Dec 2025
Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status.
Diversified Trust Co Has $4.56 Million Stake in Bristol Myers Squibb Company $BMY
05:10am, Tuesday, 30'th Dec 2025
Diversified Trust Co increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 56.0% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned
Abacus FCF Advisors LLC Raises Stock Holdings in Bristol Myers Squibb Company $BMY
03:13am, Tuesday, 30'th Dec 2025
Abacus FCF Advisors LLC raised its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 2.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The
Bristol Myers Squibb Company $BMY Stock Holdings Reduced by Valley National Advisers Inc.
06:12am, Monday, 29'th Dec 2025
Valley National Advisers Inc. cut its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 82.8% in the third quarter, according to its most recent 13F filing with the Securities and Exch
3 Drug Stocks to Buy at a Discount
04:28pm, Saturday, 27'th Dec 2025
Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight
This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year
02:30am, Saturday, 27'th Dec 2025
At the current price, investors are paying little for Bristol Myers' pipeline.
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever
05:26pm, Wednesday, 24'th Dec 2025
This drug company offers a decent balance of risk and reward, with a 4.6% yield and a payout ratio comfortably below 100%. This medical device company has a 2.9% yield and is nearing Dividend King sta
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds
09:18am, Wednesday, 24'th Dec 2025
BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 5
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
01:58am, Wednesday, 24'th Dec 2025
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY an
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
03:11pm, Tuesday, 23'rd Dec 2025
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
Jenny Harrington's top dividend plays for 2026
01:56pm, Tuesday, 23'rd Dec 2025
Jenny Harrington, CEO Gilman Hill Asset Management, joins CNBC's "Halftime Report" to share her top dividend plays for 2026.
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
11:30am, Tuesday, 23'rd Dec 2025
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
11:17am, Tuesday, 23'rd Dec 2025
Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sa
